借力推动前列腺癌 CAR-T 细胞治疗进展
Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.
The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来,采用免疫疗法治疗癌症的趋势日益明显。癌症疫苗、免疫检查点抑制剂和过继细胞疗法已使部分恶性肿瘤治疗取得显著进展。由于缺少能够改善转移性去势抵抗性前列腺癌(mCRPC)预后的有效辅助治疗,研究者正在探索上述方法作为晚期前列腺癌(PCa)的潜在治疗选择。免疫治疗策略在 PCa 治疗中尚未取得重大进展,主要原因是该恶性肿瘤的肿瘤微环境具有抑制性且突变负荷较低。因此,研究者正尝试优化免疫疗法设计和疗效,并将其与其他治疗方式整合,以应对这些挑战。迄今研究也显示出潜在临床获益。本综述全面分析免疫治疗技术在 PCa 治疗中的应用,评估其优势和障碍,旨在帮助医疗专业人员和学者全面了解该领域进展。
In recent years, there has been a growing trend towards the utilization of immunotherapy techniques for the treatment of cancer. Some malignancies have acquired significant progress with the use of cancer vaccines, immune checkpoint inhibitors, and adoptive cells therapy. Scholars are exploring the aforementioned methods as potential treatments for advanced prostate cancer (PCa) due to the absence of effective adjuvant therapy to improve the prognosis of metastatic castration-resistant prostate cancer (mCRPC). Immunotherapy strategies have yet to achieve significant advancements in the treatment of PCa, largely attributed to the inhibitory tumor microenvironment and low mutation load characteristic of this malignancy.
Hence, researchers endeavor to address these challenges by optimizing the design and efficacy of immunotherapy approaches, as well as integrating them with other therapeutic modalities. To date, studies have also shown potential clinical benefits. This comprehensive review analyzed the utilization of immunotherapy techniques in the treatment of PCa, assessing their advantages and obstacles, with the aim of providing healthcare professionals and scholars with a comprehensive understanding of the progress in this field.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。